Výsledky vyhledávání - "Saeed Fatenejad"

Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study

Autor: Eugen Feist, Saeed Fatenejad, Sergey Grishin, Elena Korneva, Michael E Luggen, Evgeniy Nasonov, Mikhail Samsonov, Josef S Smolen, Roy M Fleischmann

Publikováno v: Modern Rheumatology Journal. 17:23-26

ObjectivesTo assess the efficacy and safety of olokizumab (OKZ), a monoclonal antibody against the interleukin-6 (IL-6) cytokine, versus placebo (PBO) in patients with prior inadequate response to tumour necrosis factor inhibitors (TNFi-IRs).MethodsI

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9da1b928747915d791bf834ce64c4d62
https://doi.org/10.14412/1996-7012-2023-2-23-36

Zobrazit plný text záznamu

Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis

Autor: Josef S, Smolen, Eugen, Feist, Saeed, Fatenejad, Sergey A, Grishin, Elena V, Korneva, Evgeniy L, Nasonov, Mikhail Y, Samsonov, Roy M, Fleischmann, Marina, Stanislav

Publikováno v: The New England journal of medicine. 387(8)

The cytokine interleukin-6 is involved in the pathogenesis of rheumatoid arthritis. Olokizumab, a humanized monoclonal antibody targeting the interleukin-6 cytokine directly, is being tested for the treatment of rheumatoid arthritis.In a 24-week, pha

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d44db234971c7ad5f5b2c9ca44aec5ed
https://pubmed.ncbi.nlm.nih.gov/36001712

Zobrazit plný text záznamu

P136 Efficacy and safety of olokizumab in a phase III trial in patients with moderately to severely active RA inadequately controlled by TNF-α inhibitor therapy

Autor: Michael E. Luggen, Evgeniy L Nasonov, Sergey Grishin, Eugen Feist, Elena Korneva, Saeed Fatenejad, Mikhail Samsonov

Publikováno v: Rheumatology. 60

Background/Aims Olokizumab (OKZ) is a new humanised monoclonal antibody targeting IL-6. Here we present the results of the phase III study of OKZ in anti-TNF-IR patients. Methods Patients with moderately to severely active RA who had previously faile

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::077e50bf22933e6c1b2ffb282ddad694
https://doi.org/10.1093/rheumatology/keab247.132

Zobrazit plný text záznamu

P131 Efficacy and safety of olokizumab in a phase III trial of patients with moderately to severely active RA inadequately controlled by methotrexate: placebo and active controlled study

Autor: Elena Korneva, Sergey Grishin, Eugen Feist, Evgeniy L Nasonov, Saeed Fatenejad, Mikhail Samsonov, Anna Rowińska-Osuch, Saima Chohan

Publikováno v: Rheumatology. 60

Background/Aims Olokizumab (OKZ) is a new humanised monoclonal antibody targeting IL-6 directly. Here we present the results of a global randomised clinical trial (RCT) in patients (pts) with RA. Methods This double-blind, placebo (PBO) and active co

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8d5904116098f157c3e26041bb26359a
https://doi.org/10.1093/rheumatology/keab247.126

Zobrazit plný text záznamu

Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study

Autor: E. Zonova, Elena Korneva, Mikhail Samsonov, Mariana Ivanova, Saeed Fatenejad, D. G. Krechikova, Aleksey L Maslyanskiy, Rumen Stoilov, Evgeniy Nasonov, Eugen Feist, Mark C. Genovese

Publikováno v: Annals of the rheumatic diseases. 81(4)

ObjectiveTo evaluate the efficacy and safety of olokizumab (OKZ) in patients with active rheumatoid arthritis despite treatment with methotrexate (MTX).MethodsIn this 24-week multicentre, placebo-controlled, double-blind study, patients were randomis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0befe0904e08d59e3feebb139ec213eb
https://pubmed.ncbi.nlm.nih.gov/34344706

Zobrazit plný text záznamu

Integrated Population Pharmacokinetics of Etanercept in Healthy Subjects and in Patients With Rheumatoid Arthritis Ankylosing Spondylitis

Autor: Simon Zhou, Cathye Shu, Joseph Wadjula, Joan M. Korth-Bradley, Maria Palmisano, Thorir D. Bjornsson, Donald G. Raible, Saeed Fatenejad

Publikováno v: The Journal of Clinical Pharmacology. 51:864-875

Etanercept pharmacokinetics in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriasis were assessed separately with distinct models using population pharmacokinetics methods of limited precision. The different model struc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c73fdd29864ccdbf4bf7b292a25bb237
https://doi.org/10.1177/0091270010375961

Zobrazit plný text záznamu

Reliability and sensitivity to change of the Simple Erosion Narrowing Score compared with the Sharp-van der Heijde method for scoring radiographs in rheumatoid arthritis

Autor: D. van der Heijde, Cédric Lukas, Saeed Fatenejad, E M Dias, Robert Landewé

Publikováno v: Annals of the rheumatic diseases, 67(3), 375-379. BMJ Publishing Group

Objective: To compare the performance of a simplified scoring method for structural damage on radiographs of patients with rheumatoid arthritis (the Simple Erosion Narrowing Score or SENS) with the Sharp–van der Heijde Score (SHS) as reference. Met

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b54a6f0a4b8e25a8d9eeacc38cea3c8
https://doi.org/10.1136/ard.2007.072785

Zobrazit plný text záznamu

Level of radiographic damage and radiographic progression are determinants of physical function: a longitudinal analysis of the TEMPO trial

Autor: Robert Landewé, R. van Vollenhoven, Saeed Fatenejad, Lars Klareskog, D. van der Heijde

Publikováno v: Annals of the Rheumatic Diseases

Background: Many studies have examined the relationship between long-term radiographic damage and physical function. However, it is not known if short-term radiographic progression is also associated with physical function. Aim: To investigate the lo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86740ec251d94bf35942d2b9f84e15b8
http://europepmc.org/articles/PMC2571961

Zobrazit plný text záznamu

Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis

Autor: Catalin Codreanu, Gabriel Herrero-Beaumont, R. Zahora, Alain Cantagrel, Gabriele Valentini, Ronald Pedersen, Joseph Wajdula, D. van der Heijde, Saeed Fatenejad, Patrick Durez, Lars Klareskog, Yair Molad, Robert Landewé, D. MacPeek, George A W Bruyn

Publikováno v: Arthritis and rheumatism, 56(12), 3928-3939. John Wiley and Sons Inc.

Objective. The Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes (TEMPO) is a 3-year, double-blind, multicenter study evaluating the efficacy and safety of etanercept, methotrexate, and the combination of etanercept plus methotr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95694c4312a31a384a26301a9f4f6155
https://doi.org/10.1002/art.23141

Zobrazit plný text záznamu

Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial

Autor: Lars Klareskog, Saeed Fatenejad, A. Singh, Ronald Pedersen, D. van der Heijde, Bruce Freundlich, J Melo-Gomes, J Tornero, Catalin Codreanu

Publikováno v: Annals of the Rheumatic Diseases. 65:328-334

To compare patient reported measures of function, health related quality of life (QoL), and satisfaction with medication among patients with rheumatoid arthritis (RA) treated with methotrexate (MTX), etanercept, or both for up to 1 year.In a 52 week,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3489aec62995c5a4f96e9f976a4de468
https://doi.org/10.1136/ard.2005.035709

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání